Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/06/18 12:16:52」(JST)

wiki en

Nedaplatin (INN, marketed under the tradename Aqupla) is a platinum-based antineoplastic drug which is used for cancer chemotherapy.^[1] It produces less nausea, vomiting and nephrotoxicity than other platinum-containing drugs.^[2]

References

^ Wheate, Nial J.; Walker, Shonagh; Craig, Gemma E.; Oun, Rabbab (2010). "The status of platinum anticancer drugs in the clinic and in clinical trials". Dalton Transactions 39 (35): 8113–27. doi:10.1039/C0DT00292E. PMID 20593091.
^ Ota K (February 1996). "[Nedaplatin]". Gan to Kagaku Ryoho (in Japanese) 23 (3): 379–87. PMID 8712835.

(Japanese) Aqupla アクプラ (PDF) Shionogi & Co. March 2007.

External links

(Japanese) Official Shionogi & Co. Website

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

English Journal

Longitudinal assessments of quality of life and late toxicities before and after definitive chemoradiation for esophageal cancer.

Yamashita H, Omori M, Okuma K, Kobayashi R, Igaki H, Nakagawa K.Author information *Division of Radiation Oncology, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan. yamashitah-rad@h.u-tokyo.ac.jp.AbstractOBJECTIVE: Definitive chemoradiotherapy is often considered for locally advanced esophageal cancer. We studied the effect of chemoradiotherapy treatment on patients' quality of life and late toxicities.
Japanese journal of clinical oncology.Jpn J Clin Oncol.2014 Jan;44(1):78-84. doi: 10.1093/jjco/hyt170. Epub 2013 Nov 11.
OBJECTIVE: Definitive chemoradiotherapy is often considered for locally advanced esophageal cancer. We studied the effect of chemoradiotherapy treatment on patients' quality of life and late toxicities.METHODS: Patients undergoing definitive 5-fluorouracil and cis-diammine-glycolatoplatinum (nedapla
PMID 24220801

Nedaplatin concurrent with three-dimensional conformal radiotherapy for treatment of locally advanced esophageal carcinoma.

Shen ZT, Wu XH, Li B, Shen JS, Wang Z, Li J, Zhu XX.Author information Ze-Tian Shen, Xin-Hu Wu, Bing Li, Jun-Shu Shen, Zhen Wang, Jing Li, Xi-Xu Zhu, Department of Radiation Oncology, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, Jiangsu Province, China.AbstractAIM: To evaluate the efficacy and toxicity of nedaplatin (NDP) concurrent with radiotherapy in the treatment of locally advanced esophageal carcinoma.
World journal of gastroenterology : WJG.World J Gastroenterol.2013 Dec 28;19(48):9447-52. doi: 10.3748/wjg.v19.i48.9447.
AIM: To evaluate the efficacy and toxicity of nedaplatin (NDP) concurrent with radiotherapy in the treatment of locally advanced esophageal carcinoma.METHODS: Sixty-eight patients with locally advanced esophageal carcinoma were randomized into either a NDP group (n = 34) or a cisplatin (DDP) group (
PMID 24409075

Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.

Kajiura S, Hosokawa A, Yoshita H, Ueda Y, Ueda A, Mihara H, Ando T, Fujinami H, Nishikawa J, Ogawa K, Minemura M, Sugiyama T.Author information Departments of *Gastroenterology and Hematology, Faculty of Medicine †Department of Medical Oncology, University of Toyama, 2630 Sugitani, Toyama-shi, Toyama-ken 930-0194, Japan.AbstractOBJECTIVES:: To date, no second-line chemotherapy regimen for esophageal squamous cell carcinoma (SCC) has been established. This clinical trial aimed to assess the optimum dose of docetaxel plus nedaplatin (cis-diammine-glycolate platinum) as second-line chemotherapy.
American journal of clinical oncology.Am J Clin Oncol.2013 Dec 7. [Epub ahead of print]
OBJECTIVES:: To date, no second-line chemotherapy regimen for esophageal squamous cell carcinoma (SCC) has been established. This clinical trial aimed to assess the optimum dose of docetaxel plus nedaplatin (cis-diammine-glycolate platinum) as second-line chemotherapy.METHODS:: Patients with metasta
PMID 24322336

Japanese Journal

臨床頭頸部扁平上皮癌肺転移例に対するTPF療法変法の検討(第2報)

北村貴裕,川島貴之,小池良典 [他]
耳鼻咽喉科臨床 106(1), 61-65, 2013-01-00
NAID 40019552900

Modified TPF Chemotherapy for Pulmonary Metastases from Squamous Cell Carcinoma of the Head and Neck

北村貴裕,川島貴之,小池良典,竹林宏記,前田英美,田中順平,小坂史郎,仙波治
耳鼻咽喉科臨床 106(1), 61-65, 2013
… We report herein on 15 cases of pulmonary metastases from squamous cell carcinoma of the head and neck (SCCHN) treated with modified TPF chemotherapy (docetaxel combined with nedaplatin and 5-FU). … We modified the TPF chemotherapy using nedaplatin as a substitute for cisplatin. … nedaplatin 75 mg/m2 on day 1 and 5-FU 1000 mg/body by continuous infusion on days 1 to 4. …
NAID 130003374000

上顎洞癌に対する多剤併用選択的動注療法+放射線療法の検討

藤田芳史,鈴木一雅,森義明 [他],小松愛,波多野孝
耳鼻咽喉科臨床 105(10), 957-961, 2012-10-01
… Between 2003 and 2007, 6 patients were given intraarterial chemotherapy with cisplatin (or nedaplatin) and 5-fluorouracil. … After 2008, 4 patients were given intraarterial chemotherapy with docetaxel, cisplatin (or nedaplatin), and 5-fluorouracil. …
NAID 10031117860

Related Pictures

Putative cellular pathways of nedaplatin nephrotoxicity. This schematic | Download Energetic and Structural Comparison of Cisplatin and Analogs from DFT Calculations Nedaplatin enhanced apoptotic effects of ABT-737 in human cancer cells via Mcl-1 Platinum agents (cisplatin, nedaplatin, and carboplatin). | Research Image Cisplatin and Oxaliplatin, but Not Carboplatin and Nedaplatin, Are Substrates for Nedaplatin | ABIN412152 Nedaplatin | CAS 95734-82-0 | SCBT - Santa Cruz Biotechnology

★リンクテーブル★

リンク元

「ネダプラチン」

Nedaplatin
Systematic (IUPAC) name
	Diammine[(hydroxy-κO)acetato(2-)-κO]platinum
Clinical data
AHFS/Drugs.com	International Drug Names
Legal status	℞ (Prescription only);
Routes of; administration	IV
Identifiers
CAS Registry Number	95734-82-0
ATC code	None
PubChem	CID: 6917890
UNII	8UQ3W6JXAN
KEGG	D01416
Chemical data
Formula	C2H8N2O3Pt
Molecular mass	303.17 g/mol
	SMILES C(C(=O)[O-])[O-].N.N.[Pt+2];
(what is this?) (verify)

　　[★]

英: nedaplatin
商: アクプラ
関: 抗悪性腫瘍薬; その他の腫瘍用薬

[1] Wheate, Nial J.; Walker, Shonagh; Craig, Gemma E.; Oun, Rabbab (2010). "The status of platinum anticancer drugs in the clinic and in clinical trials". Dalton Transactions 39 (35): 8113–27. doi:10.1039/C0DT00292E. PMID 20593091.

[pmid8712835-2] Ota K (February 1996). "[Nedaplatin]". Gan to Kagaku Ryoho (in Japanese) 23 (3): 379–87. PMID 8712835.

匿名

検索

案内

案内

nedaplatin